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tions. In lightofnewevidence1–13 and throughexpertdeliberation,
this chart has nowbeen revised andexpanded (Fig.1). Some areas
wereparticularlychallengingtodevelopgiventhelimited,low-quality,




by indication.Gestation is labelled and referred to as the number of
weeks of gestation (<13weeks, 13–26weeks, and >26weeks), with
the final column being for postpartum use. However, in the case of
incompleteabortionunder13weeks,andinevitableabortionbetween
13–26weeks,womenshouldbetreatedonthebasisof theiruterine
size rather than lastmenstrualperioddating.Recommendationshave
beenaddedforinevitableabortionandcervicalpreparationbetween13
and26weeks,andforterminationofpregnancyatmorethan26weeks.
3  | NUMBER OF DOSES
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4  | ROUTE OF ADMINISTRATION


















5  | MISOPROSTOL USE IN PREGNANCIES 
WITH PREVIOUS CESAREAN OR 
TRANSMURAL UTERINE SCAR


















who have had a previous cesarean or transmural uterine scar.
Therefore,withoutevidencetosupportasaferegimen,wedonot
provide one, other than to recommend following local protocol in
these cases.
6  | MANAGEMENT OF PREGNANCY 








ity of onedoseor schedule ofmisoprostol over another for use in
pregnancies at or over 13weeks’ gestation. In making recommen-
dations,weacknowledged thatprovidersmightbekeen to identify
lowestpossibledosesbecauseofreducedadverseeffects,21 but that 
itwasalsoimportanttoconsidersuccessratesandtimetodelivery:
lowdoseshavebeenshowntobeassociatedwithalongerinduction-








any benefit over placebo.22We therefore do not recommendmis-
oprostolforretainedplacentainlatepregnancy.
8  | SECONDARY PREVENTION OF 
POSTPARTUM HEMORRHAGE FOR 
COMMUNITY- BASED PROGRAMS
Secondaryprevention isacommunity-basedstrategy thathasbeen
shown to be a comparable alternative to a universal prophylaxis
approachintwolargecommunitytrials(oneinpress).12Ratherthan
medicatingallwomenduringthethirdstageoflaborwithaprophy-
lacticdose,aregimenof800μg sublingual misoprostol (the same as 




it involves medicating far fewer women (5%–10% vs 100%), thus
causingfeweradverseeffectsandreducingcosts.
9  | CONCLUSION
The FIGO Misoprostol-only Recommended Regimens 2017 chart 
(Fig.1)istheresultofextensivecollaborationamonganinternational








































366  |     ﻿Mooris  ET  AL
expert group. It has been endorsed by the FIGO Prevention of
Unsafe AbortionWorking Group and the FIGO SafeMotherhood
andNewbornHealthCommittee,andapprovedbytheFIGOOfficers.







be used in preference over oxytocin for postpartum hemorrhage,
or instead of mifepristone plusmisoprostol for pregnancy termina-
tion, it couldbe theonlymedicineavailable insomecircumstances,
which iswhyFIGObelievesthis “misoprostol-only”chart isneeded.
Misoprostolmustcontinuetobehighlightedasanessentialmedicine




The recentWHOguidelinesonhealthworker roles inproviding
safeabortioncare23outlineawidevarietyofhealthcareproviderswho
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